Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes

Diabetes Technology and Therapeutics

Volumn 13, Issue 3, 2011, Pages 327-334

  Philotheou, Areti ^a   Arslanian, Silva ^b   Blatniczky, László ^c   Peterkova, Valentina ^d   Souhami, Elisabeth ^e   Danne, Thomas ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c Buda Children's Hospital   (Hungary)

^d RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^e SANOFI   (France)

^f Children's Hospital Auf der Bult   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN;

ADOLESCENT; ARTICLE; BEDTIME DOSAGE; BODY MASS; BOLUS INJECTION; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC COMA; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTROPHY; HYPOGLYCEMIA; INJECTION SITE SWELLING; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEIZURE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LOGISTIC MODELS; MALE;

EID: 79952157811     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0072     Document Type: Article

References (31)

1. Danne T, Lange K, Kordonouri O: New developments in the treatment of ty (Pubitemid 350043979)
2. Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ: Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2009;10:71-81.
3. American Diabetes Association: Standards of medical care in diabetes-2006. Diabetes Care 2006;29(Suppl 1):S4-S42. Erratum in: Diabetes Care 2006;29:1192.
4. Koivisto VA: The human insulin analogue insulin lispro. Ann Med 1998;30:260-266. (Pubitemid 28306450)
5. Lindholm A, Jacobsen LV: Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001;40:641-659. (Pubitemid 32954988)
6. Becker RH, Frick AD: Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47:7-20. (Pubitemid 350260885)
7. Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK: The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobinlevels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001;24:430-434. (Pubitemid 32198408)
8. Ford-Adams ME, Murphy NP, Moore EJ, Edge JA, Ong KL, Watts AP, Acerini CL, Dunger DB: Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med 2003;20:656-660. (Pubitemid 36966561)
9. Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB: Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26:799-804. (Pubitemid 36929346)
10. Annuzzi G, Del Prato S, Arcari R, Bellomo Damato A, Benzi L, Bruttomesso D, Calderini MC, Coscelli C, Fedele D, Galluzzo A, Giordano M, Giorgino R, Lapolla A, Orsini P, Pagano G, Santoro D, Riccardi G: Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. Nutr Metab Cardiovasc Dis 2001;11:168-175. (Pubitemid 33686561)
11. Tamas G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A: Glycaemic control in type 1 diabetic patients using optimized insulin aspart or human insulin in a randomized multinational study. Diabetes Res Clin Pract 2001;54:105-114. (Pubitemid 32964681)
12. Garg SK, Rosenstock J, Ways K: Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005;11:11-17. (Pubitemid 43073084)
13. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H: Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005;113:435-443. (Pubitemid 41360749)
14. Becker RH: Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther 2007; 9:109-121.
15. DiMarchi RD, Chance RE, Long HB, Shields JE, Slieker LJ: Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Res 1994; 41:93-96. (Pubitemid 24180905)
16. Campbell RK, Campbell LK, White JR. Insulin lispro: its role in the treatment of diabetes mellitus. Ann Pharmacother 1996;30:1263-1271. (Pubitemid 26367449)
17. Heise T, Nosek L, Spitzer H, Heinemann L, Niemoller E, Frick AD, Becker RH: Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007;9: 746-753. (Pubitemid 47261856)
18. Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R: Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005;37:702-707. (Pubitemid 41810494)
19. Dailey G, Rosenstock J, Moses RG, Ways K: Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004;27:2363-2368. (Pubitemid 39281386)
20. Rayman G, Profozic V, Middle M: Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. Diabetes Res Clin Pract 2007;76:304-312. (Pubitemid 46400127)
21. Becker RH, Frick AD, Burger F, Scholtz H, Potgieter JH: A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005;113:292-297. (Pubitemid 40868186)
22. Fairchild JM, Ambler GR, Genoud-Lawton CH, Westman EA, Chan A, Howard NJ, Crock PA, Nunn EA, Silink M: Insulin lispro versus regular insulin in children with type 1 diabetes on twice daily insulin. Pediatr Diabetes 2000;1:135-141.
23. Holcombe JH, Zalani S, Arora VK, Mast CJ: Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002;24:629-638. (Pubitemid 34492884)
24. Tupola S, Komulainen J, Jaaskelainen J, Sipila I: Post-prandial insulin lispro vs. human regular insulin in prepubertal children with type 1 diabetes mellitus. Diabet Med 2001; 18:654-658. (Pubitemid 32823063)
25. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K: Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005;28:2100-2105. (Pubitemid 41242451)
26. Rave K, Klein O, Frick AD, Becker RH: Advantage of premeal- injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006;29:1812-1817. (Pubitemid 44156635)
27. Becker RH, Frick AD, Nosek L, Heinemann L, Rave K: Doseresponse relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care 2007;30:2506-2507. (Pubitemid 47547782)
28. Becker R, Frick A, Teichert L, Nosek L, Heinemann L, Rave K: Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Obes Metab 2009;11:60-68.
29. Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ: Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 2003;26:2871-2875. (Pubitemid 37205561)
30. Wiegand S, Raile K, Reinehr T, Hofer S, Nake A, Rabl W, Holl RW: Daily insulin requirement of children and adolescents with type 1 diabetes: effect of age, gender, body mass index and mode of therapy. Eur J Endocrinol 2008;158:543-549. (Pubitemid 351606350)
31. Rabbone I, Bobbio A, Berger K, Trada M, Sacchetti C, Cerutti F: Age-related differences in metabolic response to continuous subcutaneous insulin infusion in pre-pubertal and pubertal children with type 1 diabetes mellitus. J Endocrinol Invest 2007;30:477-483. (Pubitemid 47496457)